The current drug development process does not capture cancer complexity or heterogeneity. This is a main reason why 96% of drugs fail when they meet patients in clinical trials, lacking efficacy in the patient population.

Orakl Oncology stands at the forefront of the techbio landscape, pioneering the use of patient tumor avatars to meticulously accelerate and de-risk drug development in collaboration with oncology players.

As a spin-out from Gustave Roussy (2023), the 4th cancer center in the world, Orakl’s boasts unique access to a vast repository of patient tissue samples and associated data. This strategic foundation positions them to scale quickly across a vast number of cancer subtypes starting with colorectal and pancreatic cancers.

The founders and team collectively bring unparalleled expertise in cancer cell biology and engineering. With over 30 years of combined academic experience across France, the UK, and the US, they are dedicated to improving cancer treatment. The company has already been funded 5M€ in equity and grants for their first developments.

Orakl Oncology is a techbio platform that is building a unique collection of patient tumor avatars, each of them combining the best biology and patient clinical and molecular data. As a spin-out from Gustave Roussy, the 4th cancer center in the world, they are positionned to scale quickly across a vast number of cancer subtypes starting with colorectal and pancreatic cancers. This combination of biology and data, scalable and supported by proprietary know-how, is an extraordinary differenciating factor.

Their cutting-edge approach involves the integration of functional testing and AI-powered analysis to predict patient response to treatments and stratify populations. They already obtained excellent predictive values, at the patient and population levels.

Orakl discovers and develops new drugs that will succeed in the clinic, for their own pipeline or in co-development with oncology companies.

–  Therapeutic areas: Oncology

–  Based in: Paris (FRANCE)

–  Employees: 1-10

–  Created in: 2023